HOUSTON – Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPD) to its p-STAT3 inhibitor,...
Latest News
HOUSTON, TX — Moleculin Biotech, Inc. (Nasdaq: MBRX), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, provided a preliminary update on recent clinical activity and expected near term milestones for its lead program MB-106 for the treatment of Acute Myeloid Leukemia...
New US IND enables parallel development of WP1122 as a cancer therapy HOUSTON – Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical-stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and Drug Administration (FDA)...
HOUSTON – Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the U.S. Food and Drug Administration (“FDA”) has approved its request for Fast Track Designation for its drug,...
Melbourne, Australia – Australian researchers have worked out how to fix a defect that causes lupus, and hope their world-first discovery will offer effective long-term treatment. Published in Nature Communications, the Monash University-led study found a way to reprogram the defective cells of lupus patients with protective molecules from healthy...
BALTIMORE — The 2009 monsoon season will soon arrive in the Asian territories and culicine mosquito populations are expected to increase. “These mosquitoes may carry the virus that causes Japanese Encephalitis (JE), which kills 10-15,000 people each year,” warned Fran Lessans, CEO of Passport Health, the largest provider of travel...
BRONX, NY—Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)—two related blood diseases that disproportionally strike older adults—are notoriously difficult to treat and associated with high relapse rates. Although new therapies have improved survival, treatment options remain limited, and the prognosis for the 50% of people who experience disease relapse remains...
London, UK – New King’s College London research reveals that interventions which improve mood can reduce levels of inflammation in people with inflammatory bowel disease by 18 per cent, compared to having no mood intervention. Researchers at the Institute of Psychiatry, Psychology & Neuroscience at King’s College London found that...
ZUG, Switzerland, February 26, 2024 – MoonLake Immunotherapeutics (NASDAQ:MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced the successful outcome of its end-of-Phase 2 interactions with the U.S. Food and Drug Administration (FDA), as well as positive feedback from its interactions with the E.U....
Munich, Germany – MorphoSys is moving ahead with its investigational BET inhibitor pelabresib, a Phase III myelofibrosis drug candidate, even though it failed to meet one of two key endpoints in a recent trial. The biopharma’s decision to stick with pelabresib follows similarly mixed results for AbbVie’s myelofibrosis drug navitoclax...